🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT04253392
Active, not recruiting Observational

RETHINK REFLUX Registry

NCT04253392 · tracked via the Priya Life Science USA tracker
Sponsor
Ethicon Endo-Surgery
Phase
Observational
Started
2020-07-08
Last updated
2026-08-28

Condition(s) studied

Gastroesophageal Reflux

Investigational drug(s) / intervention(s)

LINX Reflux Management System

LINX Reflux Management System: The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire "links" to allow esophageal distention as the bolus passes by.

Study summary

The RETHINK REFLUX Registry is a post-market prospective, multi-center, observation, single arm, long-term safety surveillance registry of subjects implanted with the LINX device. The primary objective of the study is to confirm the long-term safety profile of the LINX device and procedure (implant/explant) up to 10 years post-implant.

Eligibility

Sex
ALL
Min age
21 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: 1. Subject is \>or=21 years old 2. Subject with prospective plans for a LINX procedure 3. Subject provides written informed consent 4. Subject must be willing and able to complete questionnaires/ surveys electronically (ePROs) Exclusion Criteria: 1. Subject who was previously implanted with LINX device 2. Any reason which the Principal Investigator believes may cause the subject to be non-compliant with or unable to meet the protocol requirements (i.e. medical illness and/or limited life expectancy of less than 10 years) Note: Physicians should refer to the LINX Reflux Management System IFU for a complete list of contraindications, warnings, and precautions.

Primary outcome measure(s)

Trial sites (28)

FacilityCityRegionStatus
University of South Alabama Mobile Alabama
NW Allied Bariatric and Foregut Surgery Tucson Arizona
Keck Hospital of USC Los Angeles California
Institute of Esophageal and Reflux Surgery Englewood Colorado
University of Southern Florida (Tampa General Hospital) Tampa Florida
OSF Medical Group Peoria Illinois
Saint Elizabeth Healthcare Edgewood Edgewood Kentucky
Sparrow Hospital / Sparrow Medical Group Lansing Michigan
East Carolina University / Vidant Medical Center Greenville North Carolina
The Ohio State University Columbus Ohio
Gen Surg Assoc / Fairfield Medical Center Lancaster Ohio
Lehigh Valley Hospital - Cedar Crest Allentown Pennsylvania
Minimal Access Surgery/Prisma Health - Upstate Greenville South Carolina
Adv Surg Assoc / Self Regional Healthcare Greenwood South Carolina
Lexington Surgery West Columbia South Carolina
Panhandle Weight Loss Center Amarillo Texas
Houston Methodist Houston Texas
Bariatric Medical Institute of Texas San Antonio Texas
Richmond Surg / Henrico Doctors' Hospital Richmond Virginia
Swedish Medical Center Seattle Washington
Fox Valley Surgical Associates Appleton Wisconsin
MedUni Wien / Universitatsklinik fur Chirurgie Vienna Austria
Marien Hospital Herne Herne Germany
Univ of Milano / IRCCS Policlinico San Donato San Donato Milanese Italy
National University Hospital Singapore Singapore
Epsom Hospital Epsom United Kingdom
Guy's and St. Thomas' Hospitals London United Kingdom
RefluxUK Royal Tunbridge Wells United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04253392 on ClinicalTrials.gov ↗ ← All trials in the USA